ORMP (Oramed Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORMP Oramed Pharmaceuticals Inc ORMP
32 GF Score
Price $4.79
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals  (NAS:ORMP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Oramed Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Oramed Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.70 83.14 0.00 0.00 0.00

Oramed Pharmaceuticals Quarterly Data
Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ORMP vs CAMP, PYXS, ALEC: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


ORMP
32GF Score
Oramed Pharmaceuticals Inc ORMP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Oramed Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Oramed Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Oramed Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.027 240.849 0.037
201611 0.046 241.353 0.064
201702 0.046 243.603 0.063
201705 0.046 244.733 0.063
201708 0.046 245.519 0.063
201711 0.043 246.669 0.058
201802 0.042 248.991 0.056
201805 0.042 251.588 0.056
201808 0.038 252.146 0.050
201811 0.039 252.038 0.052
201902 0.038 252.776 0.050
201905 0.039 256.092 0.051
201908 0.039 256.558 0.051
201911 0.039 257.208 0.051
202002 0.038 258.678 0.049
202005 0.029 256.394 0.038
202008 0.029 259.918 0.037
202011 0.028 260.229 0.036
202102 0.025 263.014 0.032
202105 0.023 269.195 0.029
202108 0.021 273.567 0.026
202111 0.018 277.948 0.022
202203 0.017 287.504 0.020
202206 0.017 296.311 0.019
202209 0.017 296.808 0.019
202212 0.017 296.797 0.019
202303 0.017 301.836 0.019
202306 0.017 305.109 0.019
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.049 319.799 0.051
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:IsraelOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score

Get the complete analysis for ORMP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price